Dr. Parker is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
One MedImmune Way
Gaithersburg, MD 20878Phone+1 202-782-6205
Education & Training
- National Capital ConsortiumFellowship, Pulmonary Disease and Critical Care Medicine, 1993 - 1994
- National Capital ConsortiumFellowship, Pulmonary Disease and Critical Care Medicine, 1991 - 1993
- National Capital ConsortiumResidency, Internal Medicine, 1988 - 1991
- Uniformed Services University of the Health Sciences F. Edward Hebert School of MedicineClass of 1988
Certifications & Licensure
- MD State Medical License 1990 - 2025
Clinical Trials
- A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563). Start of enrollment: 2009 Feb 02
- D2212C00002 J-Phase II Study Start of enrollment: 2014 Jan 01
Publications & Presentations
PubMed
- 31 citationsPlasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiencyAmy D. Shapiro, Charles Nakar, Joseph M. Parker, Gary R. Albert, John E. Moran
Blood. 2018-03-22 - 77 citationsIdiopathic Pulmonary Fibrosis in United States Automated Claims. Incidence, Prevalence, and Algorithm Validation.Daina B. Esposito, Stephan Lanes, Macarius Donneyong, Crystal N. Holick, Joseph A. Lasky
American Journal of Respiratory and Critical Care Medicine. 2015-11-15 - 144 citationsA randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthmaRichard M. Nowak, Joseph M. Parker, Robert Silverman, Brian H. Rowe, Howard A. Smithline
The American Journal of Emergency Medicine. 2015-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: